As of 16 August 2023, one case of circulating vaccine-derived poliovirus type 2 (cVDPV2) was reported in Kankan making it the first case this year and since 2021. The case is linked to the Zamfara emergence from Nigeria.
As of 15 March 2023, one case of circulating vaccine derived polio virus type 2 (cVDPV2) was confirmed in Bujumbura Rural province, with onset of paralysis on 24 November 2022. Five cVDPV2-positive environmental samples were reported in the past week, from Bujumbura Mairie province, collected in November and December 2022. Viruses isolated are linked to eastern DRC's Sud-Kivu's emergence.
As of 11 March 2023, a case of acute flaccid paralysis reported in an unvaccinated child has been confirmed as circulating vaccine-derived poliovirus type 2 (cVDPV2). This is the first confirmed cVDPV2 case reported from Israel. The Israeli Ministry of Health has also reported that five asymptomatic contacts of the initial case have now tested positive for poliovirus.
As of 1 March 2023, one circulating vaccine-derived poliovirus type 2 (cVDPV2) positive environmental sample was detected in Central. It is the first positive environmental sample of circulating vaccine-derived poliovirus type 2 (cVDPV2) in the country.
As of 1 March 2023, it has been confirmed that one case of circulating vaccine-derived poliovirus type 1 (cVDPV1) was reported in Niari, detected in 2022. It is the first case of circulating vaccine-derived poliovirus type 1 (cVDPV1) in the country.
As of 6 January 2023, sequencing analysis by the Centers for Disease Control and Prevention confirmed the presence of poliovirus in a total of 101 positive samples of concern, with the last two samples collected in December 2022. A total of 94 samples have been found to be genetically linked to the individual case of paralytic polio in a Rockland County resident.
On 23 December 2022, the Canada IHR National Focal Point reported detection of vaccine derived polio virus type 2 (VDPV2) in two wastewater samples collected in August 2022 from a treatment plant and targeted sites in Canada. This followed the confirmation of a VDPV2 case in New York State, US. Sampling sites were chosen based on close connections with communities in New York and the US areas where VDPV2 was detected.
One case of circulating vaccine-derived poliovirus type 2 (cVDPV2) was reported this week, with onset of paralysis on 31 October 2022. The isolated virus is most closely related to a strain circulating in Borno, Nigeria, in 2021, and is unrelated to a cVDPV2 affecting Sudan in 2020 and which had been successfully confirmed as stopped this year.
On 25 November 2022, the National Coordination Centre for Communicable Disease Control in the Netherlands reported the detection of vaccine-derived poliovirus type 3 (VDPV3) in a sewage sample from 15 November 2022. Testing indicated the presence of WPV3-Saukett G (a component of inactivated polio vaccine). Risk of transmission is considered very low as all appropriate measures have been implemented.
One case of circulating vaccine-derived poliovirus type 2 (cVDPV2) was reported this week, with onset of paralysis on 9 October 2022. It is the first case reported from the country. Genetically-linked virus was also isolated from three healthy community contacts.
As of 4 November 2022 one circulating vaccine-derived poliovirus type 2 (cVDPV2) has been detected from an environmental sample collected on 4 October 2022. The isolated virus is most closely linked to a cVDPV2 last isolated from a case from Haut Lomami, Democratic Republic of the Congo, with an onset on 30 May 2022.
As of 14 September 2022, four cases of circulating vaccine-derived poliovirus type 1 (cVDPV1) were confirmed, the first reported in the country. Outbreak response to both cVDPV1 and cVDPV2 is being intensified.
As of 8 August 2022, vaccine derived polio virus type 2 (VDPV2) has been detected in sewage samples collected from London over the period of a few months. These samples have now been classified as ‘circulating’ (cVDPV2). As of 5 September 2022, no human case associated with VDPV2 has been reported in the United Kingdom. The population are advised to check their routine polio vaccinations are up-to-date.
As of 13 July 2022, one case of circulating vaccine-derived poliovirus type 2 (cVDPV2) has been reported. This is the first case of cVDPV2 in the country and is linked to Zamfara emergence from Nigeria.
As of 18 May 2022, health authorities in Mozambique declared an outbreak of wild poliovirus type 1 after confirming that a child in the country’s north-eastern Tete province had contracted the disease.
As of 15 April 2022, a total of seven circulating vaccine-derived poliovirus type 3 (cVDPV3) positive results have been confirmed. This includes the index case and six asymptomatic children. One child has a history of incomplete polio immunisation, the other six are unvaccinated. An additional two children with cVDPV3 detection using in-house molecular techniques are awaiting further confirmation.
Environmental samples collected between September 2021 and January 2022, have now been reclassified as circulating vaccine-derived polio virus type 3 (cVDPV3). This confirms an outbreak of cVDPV3 in the occupied Palestinian territory.
As of 17 February 2022, ongoing surveillance has confirmed a case of type 1 wild poliovirus (WPV1) in a child with onset of paralysis on 19 November 2021. The virus is genetically linked to WPV1 detected in Pakistan's Sindh province in October 2019.
As of 2 February 2022, three circulating vaccine-derived poliovirus type 2 positive environmental samples were reported; one in Arta and two in Djibouti. The virus detected is linked to the virus circulating in Yemen.
On 24 January 2022, poliovirus type 2 was confirmed in a sample from an unvaccinated 2-year-old child. The child had signs of flaccid lower paraparesis (a neurological syndrome affecting the legs). This is the second confirmed case of circulating vaccine derived polio virus type 2 in the country.